Table 2.

Top co-indications and reporter identities by formulation among patients with PsA and RA

	Tofacitinib IR		Tofacitinib MR		All tofacitinib
	N	% of case reports	N	% of case reports	N	% of case reports
PsA
Case reports	2601		2425		5026
Indications reported (most common indications reported)a
PsA	2265	87.1	1790	73.8	4055	80.7
Multipleb	337	13.0	636	26.2	973	19.4
Unknown	13	0.5	15	0.6	28	0.6
RA	4	0.2	4	0.2	8	0.2
Psoriasis	1	0.0	0	0.0	1	0.0
Alopecia universalis	1	0.0	N/A	N/A	N/A	N/A
AE reporter identity
HCPc	1294	49.8	1844	76.0	3138	62.4
Non-HCPd	1307	50.2	581	24.0	1888	37.6

RA
Case reports	39,744		24,148		63,892
Indications reported (most common indications reported)a
RA	38,372	96.6	22,616	93.7	60,988	95.5
Multiplee	1382	3.5	1542	6.4	2924	4.6
Unknown	106	0.3	88	0.4	194	0.3
Arthritis	2	0.0	3	0.0	5	0.0
PsA	3	0.0	1	0.0	4	0.0
Juvenile idiopathic arthritis	N/A	N/A	1	0.0	1	0.0
UC	1	0.0	N/A	N/A	1	0.0
AE reporter identity
HCPc	16,354	41.2	15,456	64.0	31,810	49.8
Non-HCPd	23,390	58.9	8692	36.0	32,082	50.2

Percentages are based on the total number of case reports by formulation. N/A indicates that the indication was not included in the most common indications reported for the respective formulation.

AE adverse event, HCP healthcare provider, IR immediate release, MR modified release, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis

^aCase reports could contribute to multiple indications and indications could change over time; therefore, the indications listed do not add up to 100%

^bWithin the multiple indication category, the most common co-indications (as a proportion of the co-indication in which case reports were described) were RA (46.5%), psoriasis (17.5%), and ankylosing spondylitis (3.7%)

^cHCP includes physicians, pharmacists, and ‘other HCPs’

^dNon-HCP includes consumers, lawyers, and other non-HCPs

^eWithin the multiple indication category, the most common co-indications were PsA (15.8%), osteoarthritis (10.1%), and arthritis (8.8%)